drugset / Trial / NCT05232903
Stromal Vascular Fraction (SVF) Therapy in Patients With Acute Spontaneous Intracerebral Hemorrhage (SICH).
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this pilot study is to evaluate the safety of stromal vascular fraction (SVF) therapy in patients with spontaneous intracerebral hemorrhage (SICH).
Timeline
- Start
- 2022-03-01
- Primary completion
- 2024-06-30
- Completion
- 2024-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rexlemestrocel-L | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | Rexlemestrocel-L | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | Rexlemestrocel-L | Cell therapy | 1.5e+06 cells/kg | Intravenous |